13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
34 檔
49.2%
As reported in its official Q4 2024 Form 13F filing, Novo Holdings A/S's tracked investment portfolio stood at $1.7B with 34 total positions.
In Q4 2024, Novo Holdings A/S adopted a defensive or profit-taking posture, trimming 6 positions and completely liquidating 6 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including VTI, BN, TEM) accounted for 49.2% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VTI | Vanguard Total Stock Mkt ETF | ETF-Other | 18.22% | — | — | |
| 2 | BN | Brookfield CORP | Stock-Financials | 9.73% | -2.78% | -19.83% | |
| 3 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 8.33% | — | — | |
| 4 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 8.08% | -1.03% | -9.91% | |
| 5 | ASML | ASML Holding N.V. | Stock-Tech | 6.96% | +0.81% | +24.37% | |
| 6 | CRM | Salesforce Inc | Stock-Tech | 5.95% | -2.37% | -20.26% | |
| 7 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 4.14% | — | — | |
| 8 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.76% | -2.27% | — | |
| 9 | PCVX | Vaxcyte Inc | Stock-Other | 3.72% | -1.35% | — | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 3.03% | +0.75% | NEW | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.97% | -1.69% | -3.98% | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.61% | -0.89% | -5.66% | |
| 13 | AVBP | Arrivent Biopharma Inc | Stock-Other | 2.45% | -0.60% | +1.02% | |
| 14 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.32% | -1.19% | -9.68% | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 2.00% | -1.20% | — | |
| 16 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.95% | -3.02% | EXIT | |
| 17 | ✓ | Merus N V | Stock-Other | 1.91% | — | +7.14% | |
| 18 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.53% | -0.87% | +3.77% | |
| 19 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.45% | — | +7.75% | |
| 20 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.43% | — | — | |
| 21 | ✓ | Lanzatech Global Inc | Stock-Other | 1.31% | — | — | |
| 22 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.92% | — | — | |
| 23 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.84% | — | — | |
| 24 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 25 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.79% | — | +39.13% | |
| 26 | CBLL | Ceribell Inc | Stock-Other | 0.52% | — | — | |
| 27 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.51% | -0.24% | — | |
| 28 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 29 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.42% | — | — | |
| 30 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 31 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.20% | — | — | |
| 32 | IOBTQ | Io Biotech Inc | Stock-Other | 0.19% | — | — | |
| 33 | MQ | Marqeta Inc-a | Stock-Other | 0.10% | +0.27% | — | |
| 34 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RXRX | Recursion Pharmaceuticals-a | +4.1% | NEW | New buy |
| 2 | VTI | Vanguard Total Stock Mkt ETF | +3.6% | — | Unchanged |
| 3 | ASML | ASML Holding N.V. | +1.4% | +24.37% | Add |
| 4 | CRM | Salesforce Inc | +0.9% | -20.26% | Trim |
| 5 | MIRM | Mirum Pharmaceuticals Inc | +0.9% | — | Unchanged |
| 6 | EWTX | Edgewise Therapeutics Inc | +0.7% | -9.91% | Trim |
| 7 | AVBP | Arrivent Biopharma Inc | +0.7% | +1.02% | Add |
| 8 | CBLL | Ceribell Inc | +0.5% | NEW | New buy |
| 9 | BN | Brookfield CORP | +0.5% | -19.83% | Trim |
| 10 | CRNX | Crinetics Pharmaceuticals In | +0.4% | -3.98% | Trim |
| 11 | PHVS | Pharvaris N.V. | +0.4% | — | Unchanged |
| 12 | INSM | Insmed Inc | +0.4% | — | Unchanged |
| 13 | ✓ | Mersana Therapeutics Inc | +0.4% | NEW | New buy |
| 14 | BMRN | Biomarin Pharmaceutical Inc | +0.2% | — | Unchanged |
| 15 | ✓ | Verve Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | ✓ | Merus N V | +0.2% | +7.14% | Add |
| 17 | 2655787D | Blueprint Medicines CORP | +0.1% | — | Unchanged |
| 18 | AM6 | Amicus Therapeutics Inc | +0.1% | — | Unchanged |
| 19 | ABCL | Abcellera Biologics Inc | +0.1% | — | Unchanged |
| 20 | CRGX | Cargo Therapeutics Inc | 0% | +7.75% | Add |
| 21 | IOBTQ | Io Biotech Inc | 0% | — | Unchanged |
| 22 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 23 | KYTX | Kyverna Therapeutics Inc | 0% | — | Unchanged |
| 24 | DMRA | Damora Therapeutics Inc | 0% | — | Unchanged |
| 25 | SPRO | Spero Therapeutics Inc | 0% | EXIT | Sold out |
| 26 | LXEO | Lexeo Therapeutics Inc | -0.1% | — | Unchanged |
| 27 | VRDN | Viridian Therapeutics Inc | -0.1% | -5.66% | Trim |
| 28 | CLDX | Celldex Therapeutics Inc | -0.1% | +3.77% | Add |
| 29 | RCKT | Rocket Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 30 | ZBIO | Zenas Biopharma Inc | -0.2% | +39.13% | Add |
| 31 | ✓ | Lanzatech Global Inc | -0.2% | — | Unchanged |
| 32 | MGX | Metagenomi Therapeutics Inc | -0.2% | EXIT | Sold out |
| 33 | FDMT | 4d Molecular Therapeutics In | -0.3% | — | Unchanged |
| 34 | BABA | Alibaba Group Holding-sp Adr | -0.3% | -9.68% | Trim |
| 35 | PCVX | Vaxcyte Inc | -0.5% | — | Unchanged |
| 36 | BAM | Brookfield Asset Mgmt-a | -1.5% | EXIT | Sold out |
| 37 | ALNY | Alnylam Pharmaceuticals Inc | -1.6% | EXIT | Sold out |
| 38 | CABO | Cable One Inc | -2.1% | EXIT | Sold out |
| 39 | TEM | Tempus Ai Inc-cl A | -3.1% | — | Unchanged |
| 40 | CORT | Corcept Therapeutics Inc | -5.5% | EXIT | Sold out |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 34 disclosed positions in Q4 2024.
During Q4 2024, Novo Holdings A/S's top holdings by market value included VTI (18.2%)、BN (9.7%)、TEM (8.3%). The largest single position, VTI, represented 18.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
RXRX
市值: $68.4M
Top Position Liquidated / Trimmed
CORT
前期市值: $111.6M
In Q4 2024, Novo Holdings A/S made 21 total portfolio adjustments, initiating 3 new buys, adding to 6 positions, trimming 6 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.